PubMed ID:
26198842
Public Release Type:
Journal
Publication Year: 2015
Affiliation: University of Michigan, Ann Arbor, MI, USA. dgipson@med.umich.edu.
DOI:
https://doi.org/10.1186/s12882-015-0094-5
Authors:
Wei C,
Reiser J,
Gassman J,
Gipson DS,
Herreshoff E,
Radeva M,
Savin VJ,
Sharma M,
Somers M,
Srivastava T,
Stein DT,
Trachtman H,
Vento S
Patients with resistant focal segmental glomerulosclerosis (FSGS) who are unresponsive to corticosteroids and other immunosuppressive agents are at very high risk of progression to end stage kidney disease. In the absence of curative treatment, current therapy centers on renoprotective interventions that reduce proteinuria and fibrosis. The FONT (Novel Therapies for Resistant FSGS) Phase II clinical trial (NCT00814255, Registration date December 22, 2008) was designed to assess the efficacy of adalimumab and galactose compared to standard medical therapy which was comprised of lisinopril, losartan, and atorvastatin.